Treatment of CX-4945 at the lower dose of 50 mg/kg did not significantly reduce immunopositivity for Ki-67 marker (Figure 9B,B1 and score Figure 9D), whereas the higher dose of 100 mg/kg of CX-4945 demonstrated a notable capacity to reduce the number of cells positive for the proliferative marker Ki-67 (Figure 9C,C1 and score Figure 9D) compared to the GBM untreated mice. This evidence concerns the gene MKI67 and glioblastoma.